Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Exelixis (GB:0IJO)
LSE:0IJO
Holding GB:0IJO?
Track your performance easily
0IJO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$18.67 - $27.81
Previous Close$26.15
Volume366.00
Average Volume (3M)1.80K
Market Cap
$7.49B
Enterprise Value$6.68B
Total Cash (Recent Filing)$1.00B
Total Debt (Recent Filing)$198.02M
Price to Earnings (P/E)―
Beta0.23
Next Earnings
Oct 30, 2024EPS Estimate
$0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding285,251,725
10 Day Avg. Volume1,375
30 Day Avg. Volume1,805
Standard Deviation0.11
R-Squared0.02
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)3.53
Price to Sales (P/S)3.72
Price to Cash Flow (P/CF)15.70
P/FCF Ratio16.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.32
Enterprise Value/Gross Profit3.80
Enterprise Value/Ebitda14.64
Forecast
1Y Price Target
$29.44Price Target Upside12.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
Exelixis News
Bulls Say, Bears Say
Bulls Say
Pipeline DevelopmentSeveral near-term catalysts include trial data and regulatory filings that could positively impact Exelixis.
Regulatory ApprovalsThe FDA accepted the supplemental New Drug Application for cabozantinib and assigned a review date.
Sales PerformanceCabozantinib revenues were $437.6 million, beating consensus by approximately 5%, driven by an increase in sales volume.
Bears Say
Clinical Trials And ApprovalsThe second Ph3 CONTACT-02 (mCRPC) OS analysis was not statistically significant.
Intellectual Property LitigationIP litigation is the key issue holding back the stock.
Regulatory ChallengesEXEL will not pursue a regulatory path for cabo + nivo + ipi in 1L RCC due to the lack of an OS benefit at final analysis in the COSMIC-313 trial.
---
Options Prices
Currently, No data available
---
Ownership Overview
3.02% Insiders
22.74% Mutual Funds
0.54% Other Institutional Investors
47.78% Public Companies and
Individual Investors
0IJO FAQ
What was Exelixis’s price range in the past 12 months?
Exelixis lowest share price was $18.67 and its highest was $27.80 in the past 12 months.
What is Exelixis’s market cap?
Currently, no data Available
When is Exelixis’s upcoming earnings report date?
Exelixis’s upcoming earnings report date is Oct 30, 2024 which is in 14 days.
How were Exelixis’s earnings last quarter?
Exelixis released its earnings results on Aug 06, 2024. The company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.46.
Is Exelixis overvalued?
According to Wall Street analysts Exelixis’s price is currently Undervalued.
Does Exelixis pay dividends?
Exelixis does not currently pay dividends.
What is Exelixis’s EPS estimate?
Exelixis’s EPS estimate is $0.34.
How many shares outstanding does Exelixis have?
Exelixis has 285,251,740 shares outstanding.
What happened to Exelixis’s price movement after its last earnings report?
Exelixis reported an EPS of $0.77 in its last earnings report, beating expectations of $0.31. Following the earnings report the stock price went up 11.024%.
Which hedge fund is a major shareholder of Exelixis?
Among the largest hedge funds holding Exelixis’s share is Farallon Capital Management, L.L.C.. It holds Exelixis’s shares valued at 609M.
---
Exelixis Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$29.44 (12.58% Upside)
$29.44 (12.58% Upside)
Blogger Sentiment
Bullish
GB:0IJO Sentiment 94%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $5.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.84%
12-Months-Change
Fundamentals
Return on Equity
15.06%
Trailing 12-Months
Asset Growth
-11.75%
Trailing 12-Months
Company Description
Exelixis
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.
---
0IJO Company Deck
---
0IJO Earnings Call
Q2 2024
0:00 / 0:00
---
0IJO Revenue Breakdown
89.00% Net product revenues
9.76% License revenues
1.24% Collaboration services revenues
---
0IJO Stock 12 Month Forecast
Average Price Target
$29.44
▲(12.58% Upside)
Technical Analysis
Best Analysts Covering 0IJO
1 Year
1 Year Success Rate
13/14 ratings generated profit
1 Year Average Return
+20.60%
reiterated a buy rating yesterday
Copying Jason Gerberry's trades and holding each position for 1 Year would result in 92.86% of your transactions generating a profit, with an average return of +20.60% per trade.
---